1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
602911781AC6F462785256B960066DAC4
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/professional-and-advocacy-relations-launching-international-efforts?opendocument
18
19opendocument
2054.196.208.187
21
22
23
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Patient Advocacy

Professional and Advocacy Relations: Launching International Efforts

DB Image

ID: 4264


Features:

Graphics


Pages/Slides: 6


Published: Pre-2013


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Globalization has made access to new markets fundamental for creating new opportunities for market leadership and for partnerships with other companies seeking organizations with a solid global presence. Varying regulations combined with language and cultural barriers, make it necessary for pharmaceutical companies to carefully plan their global initiatives. This 6-page document looks at best practices in launching professional and patient advocacy activities internationally.



Key findings include:
--Employ multistage trust-building initiatives to develop relationships with non-U.S. advocacy groups
--Encourage advocacy groups to take public roles with overseas governments to improve access to formularies.
--Create access strategies for top products in international affiliates to encourage activities and build buy–in for advocacy overseas

Partners include executives from ten leading pharmaceutical companies. This research originated from a Best Practices, LLC consulting project.


Industries Profiled:
Pharmaceutical; Health Care; Biotech; Medical Device


Companies Profiled:
Abbott Laboratories; AstraZeneca; Bristol-Myers Squibb; Eli Lilly; GlaxoSmithKline; Merck; Novartis; Pfizer; Roche


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.